Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin

Cathet Cardiovasc Diagn. 1996 Oct;39(2):113-8. doi: 10.1002/(SICI)1097-0304(199610)39:2<113::AID-CCD1>3.0.CO;2-I.

Abstract

No-flow has been reported after 10-15% of percutaneous interventions on degenerated saphenous vein grafts. In this prospective study of 36 degenerated saphenous vein graft lesions (32 patients), no-flow (TIMI flow < 3 in the absence of a significant lesion or dissection) occurred in 15/36 (42%) lesions. A total of 32 episodes of no-flow occurred after angioscopy (n = 14), extraction atherectomy (n = 10), balloon angioplasty (n = 2) or stent implantation (n = 6). Intragraft nitroglycerin (100-300 micrograms) alone resulted in no improvement in TIMI flow in the setting of no-reflow (TIMI flow 1.2 +/- 0.6 to 1.4 +/- 0.8, P = NS). Intragraft verapamil (100-500 micrograms) resulted in improvement in flow in all 32 episodes (TIMI flow 1.4 +/- 0.8 before, to 2.8 +/- 0.5 after verapamil, P < 0.001). Although verapamil increased TIMI flow after all episodes of no-reflow, two (6.3%) had persistent no-reflow (TIMI 1) despite verapamil, associated with non-Q wave myocardial infarction. In conclusion, treatment of no-reflow with verapamil during degenerated vein graft interventions was associated with reestablishment of TIMI 3 flow in 88% of cases. In contrast, intragraft nitroglycerin alone was ineffective for reversing no-reflow.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Calcium Channel Blockers* / administration & dosage
  • Calcium Channel Blockers* / therapeutic use
  • Coronary Angiography
  • Coronary Artery Bypass / adverse effects*
  • Female
  • Graft Occlusion, Vascular / diagnostic imaging
  • Graft Occlusion, Vascular / drug therapy*
  • Graft Occlusion, Vascular / etiology
  • Graft Survival / drug effects
  • Humans
  • Injections, Intra-Arterial
  • Male
  • Middle Aged
  • Nitroglycerin*
  • Prognosis
  • Prospective Studies
  • Regional Blood Flow / physiology
  • Saphenous Vein / physiology*
  • Vasodilator Agents* / administration & dosage
  • Vasodilator Agents* / therapeutic use
  • Verapamil* / administration & dosage
  • Verapamil* / therapeutic use

Substances

  • Calcium Channel Blockers
  • Vasodilator Agents
  • Verapamil
  • Nitroglycerin